SAN DIEGO, Dec. 13, 2010 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that Dr. Bassam Damaj, President and Chief Executive Officer, will provide company overview presentations at two conferences in San Francisco, CA on Wednesday, January 12, 2011, as follows:
| Conference: | Fourth Annual OneMedForum |
| Location: | Sir Francis Drake Hotel |
| Date: | January 12, 2011 |
| Time: | 9:00am PT |
| Webcast: | www.apricusbio.com |
| Event Description: | The OneMed Forum, a vital connecting point for emerging companies, business development executives and investors involved in the healthcare/life sciences sector. The three-day event will include industry-focused panel sessions, numerous networking opportunities and more than 125 presentations from some of the most promising emerging medical device, biotech and health information companies. |
| Conference: | Biotech Showcase 2011 |
| Location: | Parc 55 Wyndham San Francisco – Union Square |
| Date: | January 12, 2011 |
| Time: | 10:30am PT |
| Event Description: | Biotech Showcase™ provides private and public life science companies the opportunity to present to an audience of investors and business development executives. |
Dr. Damaj noted, "I look forward to presenting the Apricus Bio story at these two, key conferences. During these presentations, I intend to provide a review of corporate activities, including the status of our partnering discussions for Vitaros®, which was recently approved by Health Canada for the treatment of erectile dysfunction, as well as our commercialization plans in additional international markets, and our progress with regard to clinical development of our pipeline product candidates."
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its clinically-validated NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including its approved drug erectile dysfunction treatment, Vitaros, as well as compounds in development from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.